Advertisement

Comparison of whole-body 18F-FDG SPECT and posttherapeutic 131I scintigraphy in the detection of metastatic thyroid cancer

Published:November 22, 2007DOI:https://doi.org/10.1016/j.clinimag.2007.07.010

      Abstract

      Purpose

      The usefulness of fluorine 18 fluorodeoxyglucose (18F-FDG) imaging in differentiated thyroid cancer (DTC) has been demonstrated by investigators. The aim of this study is to compare the ability of fluorodeoxyglucose (FDG)-single photon emission computed tomography (SPECT) to detect metastatic DTC with posttherapeutic iodine131 (131I) scintigraphy.

      Methods

      239 patients (78 men, 161 women; age range, 23–76 years, mean 45 years); All patients underwent FDG-SPECT and 131I whole-body scan.

      Results

      The sensitivity of 18F-FDG and 131I imaging in the patients with high hTg levels is 48.7% (114/234) and 50.4% (118/234) respectively. However, the combined sensitivity of both protocols is 89.7% (210/234). In the patients with 131I Imaging negative, the sensitivity of 18F-FDG is 79.3%,but in the patients with 131I imaging positive, the sensitivity of 18F-FDG is only 18.6%.

      Conclusion

      This study with 131I and 18F-FDG in FDG-SPECT further demonstrates the single study of 131I whole body scan or 18F-FDG imaging can not provide a high enough sensitivity for the detection of metastatic thyroid cancer. But, the combined protocols can get better results for the staging of thyroid carcinoma with the alternating uptake of 131I and 18F-FDG.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Romer W
        • Hanauske AR
        • Ziegler S
        • Thodtmann R
        • Weber W
        • Fuchs C
        • Enne W
        • Herz M
        • Nerl C
        • Garbrecht M
        • Schwaiger M
        Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
        Blood. 1998; 91: 4464-4471
        • Hoekstra CJ
        • Paglianiti I
        • Hoekstra OS
        • Smit EF
        • Postmus PE
        • Teule GJ
        • Lammertsma AA
        Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods.
        Eur J Nucl Med. 2000; : 731-743
        • Moore JV
        • Waller ML
        • Zhao S
        • Dodd NJF
        • Acton PD
        • Jeavons AP
        • Hastings DL
        Feasibility of imaging photodynamic injure to tumors by high-resolution positron emission, tomography.
        Eur J Nucl Med. 1998; 25: 1248-1254
        • Pacak K
        • Eisenhofer G
        • Goldstein DS
        Functional imaging of endocrine tumors: role of positron emission tomography.
        Endocr Rev. 2004; 25: 568-580
        • Khan N
        • Oriuchi N
        • Higuchi T
        • Zhang H
        • Endo K
        PET in the follow-up of differentiated thyroid cancer.
        Br J Radiol. 2003; 76: 690-695
        • Wang W
        • Macapinlac H
        • Larson SM
        • Yeh SD
        • Akhurst T
        • Finn RD
        • Rosai J
        • Robbins RJ
        [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
        J Clin Endocrinol Metab. 1999; 84: 2291-2302
        • Feine U
        • Lietzenmayer R
        • Hanke JP
        • Held J
        • Wohrle H
        • Muller-Schauenburg W
        Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
        J Nucl Med. 1996; 37: 1468-1472
        • Helal BO
        • Meriet P
        • Toubert ME
        • Franc B
        • Schvartz C
        • Gauthier-Koelesnikov H
        • Prigent A
        • Syrota A
        Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
        J Nucl Med. 2001; 42: 1464-1469
        • Grunwald F
        • Schomburg A
        • Bender H
        • Klemm E
        • Menzel C
        • Bultmann T
        • Palmedo H
        • Ruhlmann J
        • Kozak B
        • Biersack HJ
        Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer.
        Eur J Nucl Med. 1996; 23: 312-319
        • Dietlein M
        • Scheidhauer K
        • Voth E
        • Theissen P
        • Schicha H
        Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer.
        Eur J Nucl Med. 1997; 24: 1342-1348
        • Grunwald F
        • Kalicke T
        • Feine U
        • Lietzenmayer R
        • Scheidhauer K
        • Dietlein M
        • Schober O
        • Lerch H
        • Brandt-Mainz K
        • Burchert W
        • Hiltermann G
        • Cremerius U
        • Biersack HJ
        Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study.
        Eur J Nucl Med. 1999; 26: 1547-1552
        • Altenvoerde G
        • Lerch H
        • Kuwert T
        • Matheja P
        • Schafers M
        • Schober O
        Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.
        Langenbecks Arch Surg. 1998; 383: 160-163
        • Grunwald F
        • Menzel C
        • Bender H
        • Palmedo H
        • Willkomm P
        • Ruhlmann J
        • Franckson T
        • Biersack HJ
        Comparison of 18FDG-PET with 131iodine and 99 mTc-sestamibi scintigraphy in differentiated thyroid cancer.
        Thyroid. 1997; 7: 327-335
        • Maxon HR
        Detection of residual and recurrent thyroid cancer by radionuclide imaging.
        Thyroid. 1999; 9: 443-446
        • Stokkel MP
        • de Klerk JH
        • Zelissen PM
        • Koppeschaar HP
        • van Rijk PP
        Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results.
        Eur J Nucl Med. 1999; 26: 1606-1609
        • Giammarile F
        • Hafdi Z
        • Bournaud C
        • Janier M
        • Houzard C
        • Desuzinges C
        • Itti R
        • Sassolas G
        • Borson-Chazot F
        Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?.
        Eur J Endocrinol. 2003; 149: 293-300
        • Frilling A
        • Gorges R
        • Tecklenborg K
        • Gassmann P
        • Bockhom M
        • Clausen M
        • Broelsch CE
        Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma.
        Surgery. 2000; 128: 1067-1074
        • Mansi L
        • Moncayo R
        • Cuccurullo V
        • Dottorini ME
        • Rambaldi PF
        Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer.
        Q J Nucl Med Imaging. 2004; 48: 82-95
        • Ong SC
        • Ng DC
        • Sundram FX
        Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
        Singapore Med J. 2005; 46: 297-301
        • Min J-J
        • Chung J-K
        • Lee YJ
        Relationship between differentiation and expression of sodium/iodide symporter or glucose transporter-1 in differentiated thyroid carcinoma.
        J Nucl Med. 2001; 42: 133
        • Lazar V
        • Bidart JM
        • Caillou B
        • Mahe C
        • Lacroix L
        • Filetti S
        • Schlumberger M
        Expression of the Na+/I− symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.
        J Clin Endocrinol Metab. 1999; 84: 3228-3234